Drugs / BM201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06368960 | Nov 2022 → Dec 2024 | cancer | InnoBM Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BM201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06368960 ↗ |
| Route | Other | “Intratumoral injection” NCT06368960 ↗ |